Analysts Hold Ratings but Slash Targets After DIAMOND Miss

The borrow market has tightened sharply but remains far from extreme. Availability has dropped to 84% — meaning roughly five shares are available for every six already borrowed — compared to over 400% as recently as last Friday and above 9,000% in late April. That is a dramatic tightening in the lending pool over a matter of days, and it confirms new short interest is entering. Cost to borrow has climbed to 5.5%, up 21% on the week and 20% over the past month, now at its highest level of the available 30-day history. Short interest itself is just 0.87% of free float — low in absolute terms, though up 12% on the week. The short score has also jumped to 48.8, its highest reading of the past 10 sessions and a notable move from the 40–43 range it occupied through most of May. None of this is a crowded short setup, but the direction of travel is clear: borrow is getting tighter and more expensive as new participants position against the stock.

Options sentiment has rotated sharply since the trial failure. The put/call ratio ended at 0.65 — below its 20-day mean of 0.94, and well below the elevated readings above 2.5 that characterised early May when the market was pricing in more downside ahead of the DIAMOND readout. With that event now behind them, the hedges have come off. What remains is a relatively call-heavy book, consistent with investors who still hold the stock looking for recovery rather than new money betting on further decline.

Institutionally, the most notable recent move came from Millennium Management, which added 897,393 shares in Q1 to reach a 1.5% stake, and Adage Capital, which built a new position of 833,209 shares in the same period. Both of those filings predate the trial failure. CEO Riad Sherif sold 25,000 shares across five days in March at prices between $26 and $28 — well above the current level. Director Christina Ackermann moved in the opposite direction, buying just over 3,700 shares across two days in mid-March at similar prices. The insider picture is mixed and dated; it does not change the post-trial calculus.

Oculis reports next on August 6. Between now and then, the focus shifts to the company's cash runway, its dry eye disease and optic neuritis pipeline — the optic neuritis programme carries a Breakthrough Therapy Designation — and whether management provides any strategic update on the OCS-01 programme. The bear case, as the Street now sees it, rests entirely on whether the remaining pipeline can support the current valuation without the DME asset. The bulls are betting it can.